Anthralin-From Psoriasis Drug to Power Adjuvant

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Anthralin is a topical psoriasis treatment that reduces keratinocyte hyper-proliferation and clears plaques.
• While effective for psoriasis, anthralin paradoxically induces inflammation in healthy skin via reactive oxygen species (ROS).
• The pro-inflammatory effect of anthralin in healthy skin presents a potential adjuvant property for transcutaneous immunization (TCI).

Purpose of the Study:

• To review the potential repurposing of anthralin as a cutaneous adjuvant for transcutaneous immunization.
• To examine the mechanistic and translational constraints for human application of anthralin in TCI.

Main Methods:

• Review of existing literature on anthralin's mechanism of action and its effects on skin inflammation.
• Analysis of pre-clinical studies combining anthralin with toll-like receptor 7 (TLR7) agonists like imiquimod (IMQ) for transcutaneous immunization.
• Evaluation of the role of cytotoxic T-cells in tumor rejection and potential for cancer therapy.

Main Results:

• Combining anthralin with imiquimod elicits strong cytotoxic T-cell responses in pre-clinical models.
• This approach is promising for cancer therapy when combined with antigenic peptides for skin penetration.
• Current evidence is primarily from mouse models, necessitating further investigation into human efficacy and safety.

Conclusions:

• Anthralin's paradoxical inflammatory effects in healthy skin offer potential as a transcutaneous immunization adjuvant.
• Further research is required to overcome mechanistic and translational hurdles before human application.
• Repurposing anthralin for TCI, particularly in cancer therapy, warrants continued investigation.